Polycyclic aromatic hydrocarbons potentiate high-fat diet effects on intestinal inflammation

Toxicology Letters

Volumn 196, Issue 3, 2010, Pages 161-167

  Khalil, Ayman ^a   Villard, Pierre Henri ^a   Dao, Maih Anh ^a   Burcelin, Rémy ^b   Champion, Serge ^a   Fouchier, Francis ^a   Savouret, Jean Francois ^c   Barra, Yves ^a   Seree, Eric ^a  

^a INSERM   (France)

^b CHU RANGUEIL   (France)

^c INSERM   (France)

Author keywords

Benzo(a)pyrene; GLP 1; High fat diet; Inflammation; Polycyclic aromatic hydrocarbon; Type 2 diabetes

Indexed keywords

BENZO[A]PYRENE; CYTOKINE; GLUCAGON LIKE PEPTIDE 1; INCRETIN; INSULIN; INTERLEUKIN 1BETA; MESSENGER RNA; POLYCYCLIC AROMATIC HYDROCARBON DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; UNCOUPLING PROTEIN 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLON; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIABETOGENESIS; ENTERITIS; ENVIRONMENTAL EXPOSURE; GENE EXPRESSION; IMPAIRED GLUCOSE TOLERANCE; INSULIN RELEASE; JEJUNUM; LIPID DIET; LIVER; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL;

ANIMALS; BENZO(A)PYRENE; DIABETES MELLITUS, TYPE 2; DIETARY FATS; ENTERITIS; GLUCAGON-LIKE PEPTIDE 1; INSULIN; INTERLEUKIN-10; INTERLEUKIN-1BETA; ION CHANNELS; MALE; MICE; MICE, INBRED C57BL; MITOCHONDRIAL PROTEINS; TUMOR NECROSIS FACTOR-ALPHA; WEIGHT GAIN;

ANIMALIA; MUS;

EID: 77953293461     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.toxlet.2010.04.010     Document Type: Article

References (38)

1. Burcelin R., Dolci W., Thorens B. Long-lasting antidiabetic effect of a dipeptidyl peptidase IV-resistant analog of glucagon-like peptide-1. Metab. Clin. Exp. 1999, 48:252-258.
2. Burcelin R., Crivelli V., Dacosta A., Roy-Tirelli A., Thorens B. Heterogeneous metabolic adaptation of C57BL/6J mice to high-fat diet. Am. J. Physiol. Endocrinol. Metab. 2001, 282:E834-E842.
3. Burcelin R., Crivelli V., Perrin C., Da Costa A., Mu J., Kahn B.B., Birnbaum M.J., Kahn C.R., Vollenweider P., Thorens B. GLUT4 AMP kinase, but not the insulin receptor, are required for hepatoportal glucose sensor-stimulated muscle glucose utilization. J. Clin. Invest. 2003, 111:1555-1562.
4. Cai D., Yuan M., Frantz D.F., Melendez P.A., Hanse L., Lee J., Shoelson S.E. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat. Med. 2005, 11:183-190.
5. Camara Y., Mampe T., Armengol J., Villarroya F., Dejean L. UCP3 expression in liver modulates gene expression and oxidative metabolism in response to fatty acids, and sensitizes mitochondria to permeability transition. Cell Physiol. Biochem. 2009, 24:243-252.
6. Cani P.D., Daubioul C.A., Reusens B., Remacle C., Catillon G., Delzenne N.M. Involvement of endogenous glucagon-like peptide-1(7-36) amide on glycaemia-lowering oligofructose in streptozotocin-treated rats. J. Endocrinol. 2005, 185:457-465.
7. Cani P.D., Amar J., Iglesias M.A., Poggi M., Knauf C., Bastelica D., Neyrinck A.M., Fava F., Tuohy K.M., Chabo C., Waget A., Delmée E., Cousin B., Sulpice T., Chamontin B., Ferrières J., Tanti J.F., Gibson G.R., Casteilla L., Delzenne N.M., Alessi M.C., Burcelin R. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007, 56:1761-1772.
8. Cani P.D., Bibiloni R., Knauf C., Waget A., Neyrinck A.M., Delzenne N.M., Burcelin R. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 2008, 57:1470-1481.
9. Capuron L., Su S., Miller A.H., Bremner J.D., Goldberg J., Vogt G.J., Maisano C., Jones L., Murrah N.V., Vaccarino V. Depressive symptoms and metabolic syndrome: is inflammation the underlying link?. Biol. Psychiatry 2008, 64:831-916.
10. Carlsson S., Midthjell K., Grill V. Smoking is associated with an increased risk of type 2 diabetes but decreased risk of autoimmune diabetes in adults: an 11-years follow-up of incidence of diabetes in Nord-Trondelag study. Diabetologia 2004, 47:1953-1956.
11. Chavin K.D., Yang S., Lin H.Z., Chatham J., Chacko V.P., Hoek J.B., Walajtys-Rode E., Rashid A., Chen C.H., Huang C.C., Wu T.C., Lane M.D., Diehl A.M. Obesity induces expression of uncoupling protein-2 in hepatocytes and promotes liver ATP depletion. J. Biol. Chem. 1999, 274:5692-5700.
12. Consonni D., Pesatori A.C., Zocchetti C., Sindaco R., D'Oro L.C., Rubagotti M., Bertazzi P.A. Mortality in a population exposed to dioxin after the seveso, Italy, accident in 1976: 25 years of follow-up. Am. J. Epidemiol. 2008, 167:847-858.
13. Denison M.S., Pandini A., Nagy S.R., Baldwin E.P., Bonati L. Ligand binding and activation of the Ah receptor. Chem. Biol. Interact. 2002, 141:3-24.
14. Eliasson B. Cigarette smoking and diabetes. Prog. Cardiovasc. Dis. 2003, 45:405-413.
15. Fane F., Yan B., Wood G., Viluksela M., Rozman K.K. Cytokines (IL-1β and TNFα) in relation to biochemical and immunological effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in rats. Toxicology 1997, 116:9-16.
16. Fernandez-Salguero P.M., Hilbert D.M., Rudikoff S., Ward J.M., Gonzalez F.J. Aryl-hydrocarbon receptor-deficient mice are resistant to 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced toxicity. Toxicol. Appl. Pharmacol. 1996, 140:173-179.
17. Fisler J.S., Warden C.H. Uncoupling proteins, dietary fat and the metabolic syndrome. Nutr. Metab. 2006, 3:38.
18. Lakka H.M., Laaksonen D.E., Lakka T.A., Niskanen L.K., Kumpusalo E., Tuomilehto J., Salonen J.T. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002, 288:2709-2716.
19. Landrigan P., Garg A., Droller D.B. Assessing the effects of endocrine disruptors in the national children's study. Environ. Health Perspect. 2003, 111:1678-1682.
20. Lee D.H., Lee I.K., Song K., Steffes M., Toscano W., Baker B.A., Jacobs D.R. A strong dose-response relation between serum concentrations of persistent organic pollutants and diabetes: results from the national health and examination survey 1999-2002. Diabetes Care 2006, 29:1638-1644.
21. Lee D.H., Lee I.K., Steffes M., Jacobs D.R. Extended analyses of the association between serum concentrations of persistent organic pollutants and diabetes. Diabetes Care 2007, 30:1596-1598.
22. Lee H.J., Ryu H.J., Shin H.D., Park B.L., Kim J.Y., Cho Y.M., Park K.S., Song J., Oh B. Associations between polymorphism in the mitochondrial uncoupling proteins (UCPs) with T2DM. Clin. Chim. Acta 2008, 398:27-33.
23. Lyte M., Bick P.H. Modulation of interleukin-1 production by macrophages following benzo(a)pyrene exposure. Int. J. Immunopharmacol. 1986, 8:377-381.
24. Michalek J.E., Pavuk M. Diabetes and cancer in veterans of operation ranch hand after adjustment for calendar period, days of spraying, and time spent in Southeast Asia. J. Occup. Environ. Med. 2008, 50:330-340.
25. Pei X.H., Nakanishi Y., Inoue H., Takayama K., Bai F., Hara N. Polycyclic aromatic hydrocarbons induce IL-8 expression through nuclear factor kappaB activation in A549 cell line. Cytokine 2002, 19:236-241.
26. Pradhan A.D., Manson J.E., Rifai N., Buring J.E., Ridker P.M. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001, 286:327-334.
27. Schmittgen T.D., Livak K.J. Analyzing real-time PCR data by the comparative C (T) method. Nat. Protoc. 2008, 3:1101-1108.
28. Stienstra R., Mandard S., Patsouris D., Maass C., Kersten S., Müller M. Peroxisome proliferator-activated receptor alpha protects against obesity-induced hepatic inflammation. Endocrinology 2007, 148:2753-2763.
29. Tamaki A., Hayashi H., Nakajima H., Takii T., Katagiri D., Miyazawa M., Hirose K., Onozaki K. Polycyclic aromatic hydrocarbon increases mRNA level for interleukin-1β in human fibroblast-like synoviocyte line via aryl hydrocarbon receptor. Biol. Pharm. Bull. 2004, 27:407-410.
30. Tian Y., Rabson A.B., Gallo M.A. Ah receptor and NF-kappaB interactions: mechanisms and physiological implications. Chem. Biol. Interact. 2002, 141:97-115.
31. Tsuboyama-Kasaoka N., Takahashi M., Kim H., Ezaki O. Up-regulation of liver uncoupling protein-2 mRNA by either fish oil feeding or fibrate administration in mice. Biochem. Biophys. Res. Commun. 1999, 257:879-885.
32. Vandebriel R.J., Meredith C., Scott M.P., Roholl P.J.M., Loveren H.V. Effects of in vivo exposure to bis(tri-n-butyltin)oxide, hexachlorobenzene, and benzo(a)pyrene on cytokine (receptor) mRNA levels in cultured rat splenocytes and on IL-2 receptor protein levels. Toxicol. Appl. Pharmacol. 1997, 148:126-136.
33. Wannamethee S.G., Shaper A.G., Perry I.J. Smoking as a modifiable risk factor of type 2 diabetes in middle-aged men. Diabetes Care 2001, 24:1590-1595.
34. Weitzman M., Cook S., Auinger P., Florin T.A., Daniels S., Nguyen M., Winickoff J.P. Tobacco smoke exposure is associated with the metabolic syndrome in adolescents. Circulation 2005, 112:862-869.
35. Will J.C., Williamson D.F., Ford E.S., Calle E.E., Thun M.J. Intentional weight loss and 13-year diabetes incidence in overweight adults. Am. J. Public Health 2002, 92:1245-1248.
36. Xie Z., Zhang J., Wu J., Viollet B., Zou M.H. Upregulation of mitochondrial uncoupling protein-2 by the AMP-activated protein kinase in endothelial cells attenuates oxidative stress in diabetes. Diabetes 2008, 57:3222-3230.
37. Yudkin J.S. Inflammation, obesity, and the metabolic syndrome. Horm. Metab. Res. 2007, 39:707-709.
38. Zozulinska D., Wierusz-Wysocka B. Type 2 diabetes mellitus as inflammatory disease. Diabetes Res. Clin. Pract. 2006, 74:12-16.